Revalesio website opens window to inflammatory disease research
Date: September 10, 2010
Revalesio Corporation, a private biotechnology company, today announced the launch of its new website, www.revalesio.com.
The new website offers a streamlined and informative tool for learning about Revalesio’s research and development activity, clinical trials and humanitarian activities. The website also provides up-to-date information regarding clinical data, publications and ongoing development of Revalesio’s novel anti-inflammatory therapeutics.
“After years of rigorous research and development, we are excited to share the many advancements our team has made in the creation and application of our novel charge-stabilized nanostructure products,” said Eric Russell, Revalesio President and CEO. “I believe we are on the cusp of many important advancements in treating inflammatory mediated diseases and we hope this new site is an informative window into our ongoing and comprehensive research.”
Learn more about Revalesio and its recent asthma study at www.revalesio.com.
Revalesio is a pioneering biotechnology company dedicated to restoring hope and transforming lives. Founded in 2000 and based in Tacoma, Washington, Revalesio has partnered with leaders in biomedical research from around the world and has an extensive patent portfolio. The company is pioneering a novel class of anti-inflammatory products and is targeting neuro-inflammatory, respiratory, cardiovascular and other inflammatory mediated diseases. For more information about Revalesio, visit www.revalesio.com.